Compare VVV & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVV | DNTH |
|---|---|---|
| Founded | 1866 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.5B |
| IPO Year | 2016 | 2018 |
| Metric | VVV | DNTH |
|---|---|---|
| Price | $33.27 | $113.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $40.00 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 2.2M | 819.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.86 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $2,285,000,000.00 | $2,036,000.00 |
| Revenue This Year | $20.80 | N/A |
| Revenue Next Year | $10.50 | $29.48 |
| P/E Ratio | $55.03 | ★ N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $28.50 | $19.84 |
| 52 Week High | $41.33 | $114.55 |
| Indicator | VVV | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 29.01 | 58.66 |
| Support Level | $32.01 | $79.27 |
| Resistance Level | $33.45 | $114.55 |
| Average True Range (ATR) | 1.19 | 5.46 |
| MACD | -0.75 | -0.17 |
| Stochastic Oscillator | 6.30 | 76.25 |
Valvoline Inc provides automotive preventive maintenance through retail stores across the U.S. and Canada, offering approximately 15-minute stay-in-your-car oil changes, battery, bulb, and wiper replacements, tire rotations, and other manufacturer-recommended maintenance. Its full-service oil changes include Valvoline oil, a new oil filter, chassis lubrication, and an 18-point maintenance check. The Company provides differential fluid, fuel system cleaning, headlight and taillight replacement, radiator service, transmission service, air conditioning, and air filter replacement. It operates and franchises approximately 2,200 Valvoline Instant Oil Change and Valvoline Great Canadian Oil Change retail locations. The majority of revenue is generated from the United States of America.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.